Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | PHASE1 | RECRUITING | 47 | — | — | Oct 20, 2025 | Oct 27, 2028 | Jun 5, 2026 | 13 | United States, Canada +3 |
ORR is defined as percentage of participants with confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by investigator assessment.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose escalation of GSK5460025 monotherapy | EXPERIMENTAL | Participants will receive GSK5460025 as monotherapy. |
| Part 2: Dose expansion of GSK5460025 monotherapy | EXPERIMENTAL | Participants will receive GSK5460025 as monotherapy. |
| Name | Type | Description |
|---|---|---|
| GSK5460025 | DRUG | GSK5460025 will be administered |
Inclusion Criteria: * Has a histologically diagnosed advanced (unresectable, metastatic or recurrent) solid tumor * Has a known dMMR/MSI-H status as determined by a certified local laboratory at the time of Pre-screening or has an unknown Mismatch repair (MMR)/ Microsatellite Instability (MSI) stat...